PURE Bioscience, Inc. (OTCMKTS:PURE) Short Interest Down 98.3% in February

PURE Bioscience, Inc. (OTCMKTS:PURE) was the target of a large decrease in short interest in February. As of February 28th, there was short interest totalling 600 shares, a decrease of 98.3% from the February 13th total of 36,200 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 59,900 shares, the days-to-cover ratio is presently 0.0 days.

PURE Bioscience Stock Performance

OTCMKTS:PURE opened at $0.06 on Friday. PURE Bioscience has a 52-week low of $0.05 and a 52-week high of $0.16. The stock has a fifty day moving average of $0.07 and a 200 day moving average of $0.08. The firm has a market capitalization of $6.15 million, a price-to-earnings ratio of -1.38 and a beta of 0.35.

PURE Bioscience (OTCMKTS:PURE) last posted its quarterly earnings data on Monday, December 16th. The company reported ($0.01) earnings per share for the quarter.

PURE Bioscience Company Profile

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.